Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Colin Miles"'
Autor:
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon
Publikováno v:
Drugs in Context, Pp 1-8 (2016)
Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to
Externí odkaz:
https://doaj.org/article/93831356d0004c618b43eff7688ea65b
Publikováno v:
F1000Research, Vol 4 (2015)
The study of primary cilia is of broad interest both in terms of disease pathogenesis and the fundamental biological role of these structures. Murine models of ciliopathies provide valuable tools for the study of these diseases. However, it is import
Externí odkaz:
https://doaj.org/article/bf4540f462c142598052bf709a916fce
Autor:
Ann Cleverly, Karim A. Benhadji, Josep Tabernero, Colin Miles, Valeria Merz, Ivelina Gueorguieva, Teresa Macarulla, T. H. Waterhouse, Michael Lahn, Davide Melisi
Publikováno v:
Cancer chemotherapy and pharmacology. 84(5)
To evaluate the exposure–overall survival (OS) relationship in patients with advanced pancreatic cancer treated with galunisertib plus gemcitabine (GG) or gemcitabine plus placebo (GP). Galunisertib 300 mg/day was given orally as intermittent dosin
Autor:
Kenneth C, Cassidy, Ivelina, Gueorguieva, Colin, Miles, Jessica, Rehmel, Ping, Yi, William J, Ehlhardt
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 48(4)
1. The disposition and metabolism of galunisertib (LY2157299 monohydrate, a TGF-βRI Kinase/ALK5 Inhibitor) was characterized following a single oral dose of 150 mg of [
Autor:
Olivier Chinot, Susan C. Guba, Jordi Rodon, Alba A. Brandes, Santosh Kesari, Ann Cleverly, Lawrence Cher, Joachim P. Steinbach, Pol Specenier, Colin Miles, Claire Smith, Juan M. Sepúlveda-Sánchez, Antoine F. Carpentier, Wolfgang Wick, David Capper, Shawn T. Estrem, Ivelina Gueorguieva, Michael Lahn, Durisala Desaiah, Helen Wheeler, Andreas von Deimling
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
International Journal of Molecular Sciences; Volume 18; Issue 5; Pages: 995
International journal of molecular sciences
International Journal of Molecular Sciences
Consejería de Sanidad de la Comunidad de Madrid
International Journal of Molecular Sciences; Volume 18; Issue 5; Pages: 995
International journal of molecular sciences
International Journal of Molecular Sciences
Galunisertib, a Transforming growth factor-beta RI (TGF-beta RI) kinase inhibitor, blocks TGF-beta-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13cc0582b9d31e648e5a8b4df55c013f
https://hdl.handle.net/20.500.12530/41636
https://hdl.handle.net/20.500.12530/41636
Autor:
Michael Lahn, N. Sada Pillay, Jonathan Michael Yingling, Ann Cleverly, Colin Miles, Ivelina Gueorguieva, Anja Stauber, Jordi Rodon
Publikováno v:
British Journal of Clinical Pharmacology. 77:796-807
Aims To identify prospectively a safe therapeutic window for administration of a novel oral transforming growth factor β (TGF-β) inhibitor, LY2157299 monohydrate, based on a pharmacokinetic/pharmacodynamic (PK/PD) model. Simulations of population p
Autor:
Antoine F. Carpentier, Lawrence Cher, Joachim P. Steinbach, Pol Specenier, Claire Smith, David Capper, Olivier Chinot, Susan C. Guba, Jordi Rodon, Michael Lahn, Alba A. Brandes, Colin Miles, Wolfgang Wick, Juan M. Sepúlveda-Sánchez, Santosh Kesari, Ann Cleverly, Helen Wheeler, Ivelina Gueorguieva, Durisala Desaiah
Publikováno v:
Neuro-oncology
The combination of galunisertib, a transforming growth factor (TGF)-beta receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma. Galunisertib (300 mg/day) was given orally 14 days on/14 day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5da0c672a4c3ee9968bc0ca6ab6b5d0
https://europepmc.org/articles/PMC4933481/
https://europepmc.org/articles/PMC4933481/
Publikováno v:
British Journal of Pharmacology. 147:379-390
The in vivo effects of a selective partial agonist for neuronal nicotinic acetylcholine receptor (nAChRs) α4β2 subtype, TC-2559, characterised recently in in vitro preparations, have been profiled. The brain bioavailability of TC-2559 and its effec
Autor:
Ivelina Gueorguieva, Durisala Desaiah, Josep Tabernero, Michael Lahn, Colin Miles, Davide Melisi, Karim A. Benhadji, T. H. Waterhouse, Ann Cleverly
Publikováno v:
Cancer Research. 76:2046-2046
Background: Transforming growth factor-beta (TGF-β) signaling pathway is active in PC. A pharmacokinetic/pharmacodynamic (PK/PD) approach integrated preclinical biomarkers and toxicity and allowed for prospective definition of therapeutic window (Gu